Literature DB >> 24412067

Constrained TRPV1 agonists synthesized via silver-mediated intramolecular azo-methine ylide cycloaddition of α-iminoamides.

Thomas O Painter1, Krisztian Kaszas2, Jacklyn Gross2, Justin T Douglas3, Victor W Day3, Michael J Iadarola2, Conrad Santini4.   

Abstract

As part of an effort to identify agonists of TRPV1, a peripheral sensory nerve ion channel, high throughput screening of the NIH Small Molecule Repository (SMR) collection identified MLS002174161, a pentacyclic benzodiazepine. A synthesis effort was initiated that ultimately afforded racemic seco analogs 12 of the SMR compound via a silver mediated intramolecular [3+2] cycloaddition of an azo-methine ylide generated from α-iminoamides 11. The cycloaddition set four contiguous stereocenters and, in some cases, also spontaneously afforded imides 13 from 12. The synthesis of compounds 12, the features that facilitated the conversion of 12-13, and their partial agonist activity against TRPV1 are discussed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic pain; Intramolecular cycloaddition; Peripheral nerve ion channels; TRPV1 agonists

Mesh:

Substances:

Year:  2013        PMID: 24412067      PMCID: PMC4568941          DOI: 10.1016/j.bmcl.2013.12.061

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  27 in total

1.  The capsaicin receptor: a heat-activated ion channel in the pain pathway.

Authors:  M J Caterina; M A Schumacher; M Tominaga; T A Rosen; J D Levine; D Julius
Journal:  Nature       Date:  1997-10-23       Impact factor: 49.962

2.  Synthesis and biological evaluation of chiral alpha-aminoanilides with central antinociceptive activity.

Authors:  Filomena Corbo; Carlo Franchini; Giovanni Lentini; Marilena Muraglia; Carla Ghelardini; Rosanna Matucci; Nicoletta Galeotti; Elisa Vivoli; Vincenzo Tortorella
Journal:  J Med Chem       Date:  2007-03-21       Impact factor: 7.446

3.  Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans.

Authors:  Narender R Gavva; James J S Treanor; Andras Garami; Liang Fang; Sekhar Surapaneni; Anna Akrami; Francisco Alvarez; Annette Bak; Mary Darling; Anu Gore; Graham R Jang; James P Kesslak; Liyun Ni; Mark H Norman; Gabrielle Palluconi; Mark J Rose; Margaret Salfi; Edward Tan; Andrej A Romanovsky; Christopher Banfield; Gudarz Davar
Journal:  Pain       Date:  2008-03-11       Impact factor: 6.961

Review 4.  Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms.

Authors:  Martin J Gunthorpe; Arpad Szallasi
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

5.  Analgesic potential of TRPV1 antagonists.

Authors:  Philip R Kym; Michael E Kort; Charles W Hutchins
Journal:  Biochem Pharmacol       Date:  2009-03-05       Impact factor: 5.858

Review 6.  Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?

Authors:  Helena Knotkova; Marco Pappagallo; Arpad Szallasi
Journal:  Clin J Pain       Date:  2008-02       Impact factor: 3.442

7.  Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain "C-region".

Authors:  C S Walpole; R Wrigglesworth; S Bevan; E A Campbell; A Dray; I F James; K J Masdin; M N Perkins; J Winter
Journal:  J Med Chem       Date:  1993-08-06       Impact factor: 7.446

8.  TRPV1 antagonists: the challenges for therapeutic targeting.

Authors:  Neelima Khairatkar-Joshi; Arpad Szallasi
Journal:  Trends Mol Med       Date:  2008-12-25       Impact factor: 11.951

Review 9.  The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.

Authors:  Arpad Szallasi; Daniel N Cortright; Charles A Blum; Samer R Eid
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

Review 10.  Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.

Authors:  Martin J Gunthorpe; Boris A Chizh
Journal:  Drug Discov Today       Date:  2008-12-26       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.